Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Lymphoma 3 Stomatitis 2 Small Cell Lung Carcinoma 2 Neoplasms 2 Mucositis 2 Mouth Neoplasms 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Small Cell 2 Brain Neoplasms 2 Spinal Cord Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 98 Gemcitabine 70 Paclitaxel 59 Docetaxel 52 Carboplatin 49 Cisplatin 40 Nivolumab 39 Capecitabine 35 Pemetrexed 33 Fluorouracil 32 Bevacizumab 32 Cetuximab 31 130-nm albumin-bound paclitaxel 28 Trastuzumab 26 Irinotecan 24 Albumin-Bound Paclitaxel 24 Fulvestrant 22 Leucovorin 20 Oxaliplatin 18 Panitumumab 17 abemaciclib 16 Ipilimumab 16 Cyclophosphamide 15 cemiplimab 14 atezolizumab 14 Letrozole 14 palbociclib 12 Lapatinib 12 Drug Therapy 12 Doxorubicin 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasm Metastasis × RRx-001 × Clear all

NCT02801097 2022-05-17

PAYLOAD

EpicentRx, Inc.

Phase 1 Terminated

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡